Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

Pfizer gains controlling interest in Redvax
February 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

NEW YORK—Pfizer Inc. has announced the acquisition of a controlling interest in Redvax GmbH, a spinoff from Redbiotec AG. With that controlling interest comes access to Redvax' preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program. CMV is a herpes virus infecting 50 to 90 percent of adults, though a majority remain asymptomatic. Children born with CMV face potentially serious and lifelong consequences, with one of five children with CMV experiencing hearing loss and severe neurologic disorders. The U.S. Centers for Disease Control and Prevention estimate that some 5,000 children in the United States develop lasting CMV-caused health problems each year, and the Institute of Medicine has named the development of a CMV vaccine as a top priority. Healthcare costs associated with CMV disease total at least $1.86 billion annually in the United States.
 
Code:

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.